Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials

OBJECTIVES: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour actively in models of HER2-positive breast cancer. However, the efficacy of trastuzumab in combination with lapatinib remains contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhi-qiao, Zhang, Yan, Li, Ning, Liu, Pei-jie, Gao, Ling, Gao, Xin, Tie, Xiao-jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353336/
https://www.ncbi.nlm.nih.gov/pubmed/28289045
http://dx.doi.org/10.1136/bmjopen-2016-013053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353336/
https://www.ncbi.nlm.nih.gov/pubmed/28289045
http://dx.doi.org/10.1136/bmjopen-2016-013053

Ejemplares similares